Fig. 5

Correlations between MRD negativity duration, PFS, and MRD dynamics, and identification of predictors associated with sustained MRD negativity. (A) PFS comparison among patients with sustained MRD negativity, persistent MRD positivity, and those who lost MRD-negative status post-BCMA CAR-T therapy. (B, C, D) PFS among MRD-negative patients sustained at 12, 24, and 36 months. (E) Probability of sustained MRD negativity stratified by bone marrow burden. (F) Probability of sustained MRD negativity stratified by triple exposure. (G) Probability of sustained MRD negativity stratified by achieving CR at the third month. (H) Probability of sustained MRD negativity stratified by CAR-T persistence time. CAR, chimeric antigen receptor; CR, complete response; Mo, month; MRD, minimal residual disease; PFS, progression-free survival